Rizvangul Iminova

Rizvangul Iminova


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2026 in Molecules
Verified
Journal Article
Open access
PDF file
RIRizvangul Iminova
Rizvangul Iminova
GBGulzat Ergaziyevna Berganayeva
Gulzat Ergaziyevna Berganayeva
AZAliya Zhurtbayeva
Aliya Zhurtbayeva
LALazzat Abdurakhmanova
Lazzat Abdurakhmanova
AAAlmagul Almabekova
Almagul Almabekova
MDMoldyr Dyusebaeva
Moldyr Dyusebaeva
Poly(ethylene glycol) (PEG) has long stood as the prevailing standard in drug delivery, celebrated for its capacity to enhance solubility, extend circulation, and improve pharmacological performance. Nevertheless, the emergence of anti-PEG antibodies, accelerated clearance, and limited biodegradability increasingly undermine its role as a universal solution. In response, a new generation of polymers has been developed to address these shortcomings, offering the potential to sustain or surpass PEG’s benefits while mitigating immunogenicity, improving biocompatibility, and enabling finer control over therapeutic fate. This review examines current research to articulate a coherent perspective on the replacement of PEG, tracing how advances in polymer design are reshaping the foundations of targeted drug delivery. Taken together, these developments signal not only a corrective to the limitations of PEG but also a broader paradigm shift toward safer, more versatile, and clinically translatable systems that define the next frontier in precision therapeutics.

21 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RIRizvangul Iminova
Rizvangul Iminova
GBGulzat Ergaziyevna Berganayeva
Gulzat Ergaziyevna Berganayeva
Daniil ShepilovDaniil Shepilov
Daniil Shepilov
AAAlmagul Almabekova
Almagul Almabekova
AZAliya Zhurtbayeva
Aliya Zhurtbayeva
MDMoldyr Dyusebaeva
Moldyr Dyusebaeva
Poly(ethylene glycol) (PEG) has long stood as the prevailing standard in drug delivery, celebrated for its capacity to enhance solubility, extend circulation, and improve pharmacological performance. Nevertheless, the emergence of anti-PEG antibodies, accelerated clearance, and limited biodegradability increasingly undermine its role as a universal solution. In response, a new generation of polymers has been developed to address these shortcomings, offering the potential to sustain or surpass PEG’s benefits while mitigating immunogenicity, improving biocompatibility, and enabling finer control over therapeutic fate. This review examines current research to articulate a coherent perspective on the replacement of PEG, tracing how advances in polymer design are reshaping the foundations of targeted drug delivery. Taken together, these developments signal not only a corrective to the limitations of PEG but also a broader paradigm shift toward safer, more versatile, and clinically translatable systems that define the next frontier in precision therapeutics.